New Research Questions Whether Beta-Blockers Should Be Prescribed Indefinitely After Heart Attacks

Every year, more than 3 million people worldwide suffer an ST-elevation myocardial infarction—the most severe type of heart attack [1]. For the past four decades, survivors who walk out of the hospital have almost universally been handed a prescription for a beta-blocker, a class of drugs that slows heart rate and lowers blood pressure, with instructions to take it for life. More than 80% of patients with uncomplicated heart attacks are discharged on these medications [2]. Now, a rapid succession of large clinical trials is forcing cardiologists to confront an uncomfortable question: has the medical profession been overtreating tens of millions of patients based on evidence that predates the modern era of cardiac care?

The Foundation: Trials From a Different Era

The case for indefinite beta-blocker use after a heart attack rests on trials conducted in the late 1970s and early 1980s. The Beta-Blocker Heart Attack Trial (BHAT), which enrolled 3,837 patients between 1978 and 1980, found that propranolol reduced total mortality by 26% over a mean follow-up of 25 months [3]. The Norwegian Multicenter Study Group trial, involving 1,884 patients, reported an even more striking 42.5% reduction in all-cause mortality at 33 months [3]. Later, the CAPRICORN trial (2001) showed a 23% reduction in all-cause mortality and a 41% reduction in recurrent MI with carvedilol, though specifically in patients with reduced left ventricular ejection fraction (LVEF)—the heart's pumping efficiency [3].

These results were decisive, and guidelines worldwide incorporated beta-blockers as a cornerstone of post-MI therapy. But those trials were conducted in what cardiologists call the "pre-reperfusion era." Patients in the 1980s did not routinely receive emergency percutaneous coronary intervention (PCI)—the catheter-based procedure that reopens blocked arteries, now standard within hours of a heart attack. They were not on high-intensity statins, dual antiplatelet therapy, or ACE inhibitors. The patients in BHAT had substantially higher baseline mortality risk than a typical heart attack survivor today.

"Beta-blockers have long been foundational treatment after acute MI; however, supporting evidence predates modern standards of care," said Prof. Borja Ibáñez, principal investigator of the REBOOT-CNIC trial [4].

The New Evidence: Four Trials, 22,000 Patients

Between 2024 and 2025, four major randomized controlled trials reported results that collectively challenge the status quo.

Source: Trial Publications

Data as of Aug 30, 2025CSV

REDUCE-AMI (2024), a Swedish registry-based trial published in the New England Journal of Medicine, randomized 5,020 patients with acute MI and preserved LVEF (≥50%) to long-term beta-blocker therapy or no beta-blockers. Over a median 3.5 years, the primary composite of all-cause death or nonfatal MI occurred in 7.9% of the beta-blocker group versus 8.3% of the control group—a statistically insignificant difference (hazard ratio 0.96; 95% CI 0.79–1.16; p = 0.64) [5][6].

ABYSS (2024), a French multicenter trial of 3,698 patients who had been on beta-blockers for at least six months after MI, randomized participants to either stop or continue their medication. The trial failed to demonstrate that interruption was noninferior to continuation: the primary composite endpoint (death, MI, stroke, or cardiovascular hospitalization) occurred in 23.8% of the interruption group versus 21.1% of the continuation group [7]. Notably, stopping beta-blockers did not improve quality of life—a finding that surprised investigators, since side-effect relief was a primary rationale for the trial.

REBOOT-CNIC (2025), presented at ESC Congress 2025 and simultaneously published in the NEJM, was the largest of the modern trials, enrolling 8,505 patients across 109 centers in Spain and Italy. Patients with MI and LVEF above 40% were randomized to beta-blocker therapy or no beta-blockers. After a median follow-up of 3.7 years, the primary composite of all-cause death, nonfatal reinfarction, or heart failure admission showed no significant difference (HR 1.04; 95% CI 0.89–1.22; p = 0.63) [4][8].

BETAMI-DANBLOCK (2025), a combined Norwegian-Danish trial of 5,574 patients with MI and LVEF ≥40%, found a different result. After a median 3.5 years, the composite primary endpoint—which included all-cause mortality, new MI, unplanned revascularization, ischemic stroke, heart failure, and malignant arrhythmias—occurred in 14.2% of the beta-blocker group versus 16.3% of the control group (HR 0.85; 95% CI 0.75–0.98; p = 0.027). Beta-blockers significantly reduced new MI (HR 0.73; 95% CI 0.59–0.92), though not all-cause mortality alone (HR 0.94; 95% CI 0.73–1.21) [9][10].

The Subgroup That Changes Everything: Mildly Reduced Ejection Fraction

The apparent contradiction between REBOOT-CNIC and BETAMI-DANBLOCK dissolves when the data is examined by ejection fraction subgroups. An individual patient data meta-analysis published in The Lancet, pooling results from REBOOT, BETAMI, DANBLOCK, and the CAPITAL-RCT trial, identified 1,885 patients with mildly reduced LVEF (40–49%) and no history of heart failure. In this group, beta-blockers produced a 25% relative reduction in the composite of all-cause death, new MI, or heart failure—from 14.4% to 10.7% [11][12].

Both research teams converged on the same interpretation. "They all point in this direction—that there is a benefit in the subgroup with ejection fraction below 50%," said Prof. Eva Prescott of the BETAMI-DANBLOCK trial [8]. For patients with truly preserved LVEF (≥50%), a separate meta-analysis of nearly 18,000 patients found beta-blockers did not reduce the primary composite endpoint (8.1% vs. 8.3%; HR 0.97) [13].

This distinction matters enormously. Approximately half of heart attack survivors do not develop heart failure or reduced ejection fraction [2]. For these patients—potentially millions worldwide—indefinite beta-blocker therapy appears to offer no measurable cardiovascular benefit.

The Side-Effect Burden

Beta-blockers are not benign pills. A 2002 meta-analysis in JAMA found that beta-blocker therapy was associated with an absolute increase of 18 additional reports of fatigue per 1,000 patients per year, and 5 additional reports of sexual dysfunction per 1,000 patients per year [14]. While the same analysis found no statistically significant association with depressive symptoms, real-world reporting suggests higher rates: the FDA Adverse Event Reporting System (FAERS) has documented substantial reports of fatigue, dizziness, depression, and exercise intolerance associated with commonly prescribed beta-blockers [15].

These effects are not trivial for patients who have recovered from a heart attack and are trying to return to normal life. Exercise intolerance—the inability to raise heart rate adequately during physical activity—is particularly counterproductive, given that cardiac rehabilitation and regular exercise are themselves evidence-based interventions for reducing recurrent cardiovascular events. Older beta-blockers like propranolol and atenolol carry higher side-effect burdens than newer, more selective agents like bisoprolol and nebivolol [14], but even newer agents dampen the heart-rate response to exertion.

When patients derive clear mortality benefit from a drug, side effects are a reasonable tradeoff. When the benefit is absent, they become an uncompensated burden.

Guidelines in Flux

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes, published in Circulation, still recommends initiating beta-blockers within 24 hours of ACS as a Class I (strongest) recommendation with Level of Evidence A [16]. However, cardiologists are already noting that the guidelines, which were largely finalized before the ESC 2025 data was presented, do not fully reflect the latest evidence.

A perspective published in the Journal of the American College of Cardiology argued that "a reasonable case could be made to retire β-blockers from the guidelines" for preserved-EF patients, or at minimum to downgrade the recommendation to Class IIb (weak, benefit uncertain) [17]. The ESC has already moved in this direction: its current ACS guidelines recommend beta-blockers for patients with LVEF ≤40% (Class I) but give only a Class IIa recommendation (moderate, benefit likely) for routine use in all ACS patients [18].

Guideline revision in cardiology is notoriously slow. Major guidelines are typically updated every 5 to 8 years, though focused updates can be issued sooner when the evidence warrants it. The lag between evidence and practice change can be even longer: studies have shown that it takes an average of 17 years for research evidence to fully reach clinical practice [19]. Given the strength and consistency of recent trial data, however, most experts anticipate faster movement on this question.

"This is one of these few cases that [it] is clearly the final nail in the coffin," Ibáñez said, predicting that "the next iterations of ACS guidelines [will] reflect the new data" [13].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Who Benefits, Who Doesn't: A Sharper Picture

The emerging consensus can be summarized by ejection fraction:

• LVEF < 40% (reduced ejection fraction with heart failure): Beta-blockers remain strongly supported. These patients were excluded from the recent trials, and existing evidence from CAPRICORN and heart failure trials continues to show mortality benefit [3][10].
• LVEF 40–49% (mildly reduced ejection fraction): The meta-analysis suggests meaningful benefit, with a 25% relative risk reduction in the composite endpoint. Guidelines are likely to maintain or strengthen recommendations for this group [11][12].
• LVEF ≥ 50% (preserved ejection fraction): Nearly 18,000 patients across multiple trials show no benefit from beta-blockers on death, MI, or heart failure endpoints. This is the group where deprescribing is most strongly supported [5][6][13].
• Patients with ongoing angina or arrhythmia: Beta-blockers have separate, well-established indications for symptom management in these conditions, independent of post-MI secondary prevention [16].

Critics of the new evidence raise legitimate concerns. The ABYSS trial's failure to meet its noninferiority endpoint is a cautionary note: abruptly stopping beta-blockers may carry risks, including rebound tachycardia and a transient increase in cardiovascular hospitalizations [7]. Johanne Silvain, a cardiologist at Pitié-Salpêtrière Hospital in Paris, cautioned that "the message should not be 'stop beta-blockers after MI,' but rather 'consider withdrawal only when the residual ischemic and arrhythmic risk is truly minimal'" [13].

Follow the Money—or Lack of It

The financial dynamics of this debate are unusual. The beta-blockers in question—metoprolol, bisoprolol, carvedilol, atenolol—are almost all off-patent generics, costing pennies per day in most markets. No pharmaceutical company stands to profit significantly from their continued use, nor does any company have a strong financial incentive to fund trials that might eliminate a competitor's product.

This cuts both ways. The absence of commercial interest helps explain why it took four decades to conduct modern trials questioning beta-blocker use: there was no profit motive to fund them. The recent trials were largely supported by government research agencies and academic institutions in Sweden, France, Spain, Italy, Norway, and Denmark [4][5][7][9].

Conversely, a guideline change that eliminates beta-blockers for preserved-EF patients would not create a "gap" that newer, expensive drugs could fill. These patients would simply take one fewer medication. The financial winners, if any, would be healthcare systems and patients themselves, through reduced pharmacy costs and fewer side-effect-related medical visits.

Real-World Discontinuation: What Happens When Patients Stop

Outside of clinical trials, many patients and physicians have already begun tapering beta-blockers. Claims data and registry studies show that adherence to beta-blockers drops over time: approximately 79% of patients remain on them at one year post-MI, but this falls substantially by three to five years [2]. Whether this represents informed deprescribing or simple nonadherence is often unclear.

A nationwide cohort study tracking patients from their first beta-blocker prescription found that cumulative adherence at one year was 81.1% for beta-blockers versus 85.9% for calcium channel blockers, with lower adherence among patients who experienced side effects [15]. This real-world attrition suggests that many patients are already "voting with their feet," discontinuing a medication that makes them feel worse without perceiving benefit.

The ABYSS trial, however, offers a note of caution for unmonitored discontinuation. Even in a controlled setting with physician supervision, stopping beta-blockers led to more cardiovascular hospitalizations, particularly for angina, along with higher heart rates and blood pressure [7]. This suggests that discontinuation—when it happens—should be a deliberate, monitored process rather than a patient simply stopping their pills.

The Deprescribing Challenge

If guidelines formally shift, the practical challenge is substantial. Millions of patients worldwide are currently on indefinite beta-blocker regimens after MI. Identifying which patients have preserved versus reduced ejection fraction requires echocardiographic data that may not be readily accessible years after the initial event. Primary care physicians, who manage most of these prescriptions long-term, may lack the cardiology expertise or clinical infrastructure to safely stratify and taper patients.

There is also the problem of clinical inertia and medicolegal risk. Physicians who have prescribed beta-blockers for decades may be reluctant to stop a medication that "isn't causing obvious harm," even when the evidence for benefit evaporates. The medicolegal calculus is asymmetric: a physician who continues an established medication faces essentially no liability risk, while one who stops a medication and sees a patient subsequently suffer a cardiac event faces potential scrutiny—regardless of whether the two events are causally related.

This asymmetry could create what some cardiologists worry about: a two-tier standard of care, where patients treated by early adopters of new evidence receive updated, evidence-based therapy, while patients of more conservative physicians continue on outdated regimens. The gap may fall along socioeconomic and geographic lines, with academic medical centers and well-resourced health systems adapting faster than community practices and underserved settings.

What Comes Next

The field is moving toward a more individualized approach. Rather than the binary question of "beta-blockers for all post-MI patients or none," the evidence now supports risk stratification based on ejection fraction, with additional consideration of ongoing symptoms like angina or arrhythmia.

Several steps are likely in the near term. Guideline committees at the ACC, AHA, and ESC are expected to issue focused updates or addenda addressing the new trial data. Clinical decision-support tools will need to incorporate ejection fraction thresholds into beta-blocker recommendations. And perhaps most importantly, patient education campaigns will need to convey a nuanced message: beta-blockers remain critical for some heart attack survivors, but may be unnecessary for others.

For the millions of patients currently taking a daily pill that may no longer be helping them, the path forward requires not just new guidelines, but the clinical infrastructure and physician willingness to act on them. The evidence has arrived. The question now is how long the practice takes to follow.